Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Dow
Colorcon
Baxter
Harvard Business School
AstraZeneca
McKinsey

Last Updated: August 19, 2022

GEODON Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


When do Geodon patents expire, and when can generic versions of Geodon launch?

Geodon is a drug marketed by Viatris and Pfizer Inc and is included in three NDAs.

The generic ingredient in GEODON is ziprasidone mesylate. There are twenty-three drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the ziprasidone mesylate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Geodon

A generic version of GEODON was approved as ziprasidone mesylate by GLAND PHARMA LTD on December 26th, 2019.

  Try it Free

Drug patent expirations by year for GEODON
Drug Prices for GEODON

See drug prices for GEODON

Drug Sales Revenue Trends for GEODON

See drug sales revenues for GEODON

Recent Clinical Trials for GEODON

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Astellas Pharma Global Development, Inc.Phase 2
Duke UniversityPhase 1
National Heart, Lung, and Blood Institute (NHLBI)Phase 1

See all GEODON clinical trials

Pharmacology for GEODON
Anatomical Therapeutic Chemical (ATC) Classes for GEODON
Paragraph IV (Patent) Challenges for GEODON
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
GEODON Capsules ziprasidone hydrochloride 20 mg, 40 mg, 60 mg and 80 mg 020825 5 2005-02-07

US Patents and Regulatory Information for GEODON

GEODON is protected by zero US patents and one FDA Regulatory Exclusivity.

FDA Regulatory Exclusivity protecting GEODON

INFORMATION ADDED TO SECTION 8.4 OF THE LABELING TO DESCRIBE THE RESULTS FROM PEDIATRIC STUDIES
Exclusivity Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Viatris GEODON ziprasidone hydrochloride CAPSULE;ORAL 020825-001 Feb 5, 2001 AB RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Viatris GEODON ziprasidone hydrochloride CAPSULE;ORAL 020825-004 Feb 5, 2001 AB RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Viatris GEODON ziprasidone hydrochloride CAPSULE;ORAL 020825-002 Feb 5, 2001 AB RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Viatris GEODON ziprasidone hydrochloride CAPSULE;ORAL 020825-003 Feb 5, 2001 AB RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for GEODON

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pfizer Inc GEODON ziprasidone hydrochloride SUSPENSION;ORAL 021483-001 Mar 29, 2006 See Plans and Pricing See Plans and Pricing
Viatris GEODON ziprasidone hydrochloride CAPSULE;ORAL 020825-002 Feb 5, 2001 See Plans and Pricing See Plans and Pricing
Pfizer Inc GEODON ziprasidone hydrochloride SUSPENSION;ORAL 021483-001 Mar 29, 2006 See Plans and Pricing See Plans and Pricing
Viatris GEODON ziprasidone mesylate POWDER;INTRAMUSCULAR 020919-001 Jun 21, 2002 See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for GEODON

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0904273 PA2003004,C0904273 Lithuania See Plans and Pricing PRODUCT NAME: ZIPRASIDONUM (5-(2-(4-(1,2-BENZIZOTIAZOL-3-IL)-1-PIPERAZINIL)ETIL)-6-CHLOR-1,3-DIHIDRO-2H-INDOL-2-ONAS); REGISTRATION NO/DATE: 02/7887/8 20021002
0904273 PA2003004 Lithuania See Plans and Pricing PRODUCT NAME: ZIPRASIDONUM (5-(2-(4-(1,2-BENZIZOTIAZOL-3-IL)-1-PIPERAZINIL)ETIL)-6-CHLOR-1,3-DIHIDRO-2H-INDOL-2-ONAS); REGISTRATION NO/DATE: 02/7887/8 20021002
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Moodys
Medtronic
Colorcon
Boehringer Ingelheim
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.